Garraud O, Diouf A, Holm I, Perraut R, Longacre S
Unité d'Immunologie, Institut Pasteur, Dakar, Sénégal.
Immunology. 1999 Jul;97(3):497-505. doi: 10.1046/j.1365-2567.1999.00804.x.
A baculovirus recombinant antigen corresponding to the C-terminal 19 000 MW fragment of Plasmodium falciparum merozoite surface protein 1 (MSP119), has been used to prime T cells from individuals with no previous exposure to malaria, to provide help for the induction of a parasite specific antibody response in vitro. Although MSP119 alone could induce a small but detectable T-cell response, which included interleukin-4 (IL-4) secretion, this response was significantly increased by the presence of IL-2. In addition, IL-4 was shown to synergize with IL-2 for the induction of antigen-specific T-cell responses. If interferon-gamma (IFN-gamma), IL-12, or neutralizing anti-IL-4 antibody was present at the time of priming, the T-cell responses were abolished. Parasite-specific immunoglobulin G (IgG) could be detected after secondary restimulation with MSP119, IL-10 and anti-CD40 monoclonal antibody in cultures containing MSP119 primed T cells, autologous B cells, IL-2 and IL-4. No antibody was secreted in the absence of primed T cells in this B-cell culture assay. These data show that recombinant MSP119, a leading malaria vaccine candidate, can prime non-immune human lymphocytes under defined in vitro experimental conditions, which include regulatory cytokines and/or other costimulatory molecules. This is a complementary approach for exploring immunogenic mechanisms of potential vaccine candidates such as P. falciparum antigens in humans.
一种杆状病毒重组抗原,对应于恶性疟原虫裂殖子表面蛋白1(MSP1)的C末端19000分子量片段(MSP119),已被用于激发此前未接触过疟疾的个体的T细胞,以在体外为诱导寄生虫特异性抗体反应提供帮助。尽管单独的MSP119可诱导出小但可检测到的T细胞反应,其中包括白细胞介素-4(IL-4)分泌,但IL-2的存在可使该反应显著增强。此外,IL-4被证明与IL-2协同作用以诱导抗原特异性T细胞反应。如果在激发时存在干扰素-γ(IFN-γ)、IL-12或中和性抗IL-4抗体,则T细胞反应被消除。在用MSP119、IL-10和抗CD40单克隆抗体对含有经MSP119激发的T细胞、自体B细胞、IL-2和IL-4的培养物进行二次再刺激后,可检测到寄生虫特异性免疫球蛋白G(IgG)。在该B细胞培养试验中,在没有激发的T细胞的情况下不分泌抗体。这些数据表明,重组MSP119作为一种主要的疟疾疫苗候选物,可在特定的体外实验条件下,包括调节性细胞因子和/或其他共刺激分子,激发非免疫人类淋巴细胞。这是一种探索潜在疫苗候选物(如恶性疟原虫抗原)在人类中的免疫原性机制的补充方法。